The Higher Institute of Health denies that there are delays in the development of the drug. No stop, therefore, simply “this phase has not yet been completed”. The research, adds the Institute, “has not under arrest, but is following the normal iter of consolidation as for all other potential vaccination models”.
The current phase, moreover, does not allow to make a quantitative estimate of the effectiveness and effective duration of the vaccination cover”. The technology of the vaccine subject of study “is based on the activation of the immunity induced by the cells cd8 t, is original compared to the others in oo and are considering further possible developments”.